The antihypertensive activity of losartan potassium losartan, Cozaar 100, an angiotensin II receptor antagonist, /anxiety-medication-lexapro-panic-attacks.html evaluated in a parallel week, double-blind, placebo-controlled trial in losartan 50 to 100 patients with mild-to-moderate hypertension.
Sitting diastolic losartan 50 to 100 pressure was also evaluated losartan the end of the trial 100 a 1-week off-drug period to assess for rebound hypertension. Based on trough losartan 50 to 100 pressures at week 12, active drug both arms was more effective than placebo in lowering sitting diastolic blood pressure, with a very small additional benefit associated with increasing the dose of losartan to mg in patients who did not reach the target blood pressure after the first 6 weeks losartan 50 to 100 losartan 50 mg.
There was no evidence of rebound hypertension during 1 week after withdrawal of losartan 50 losartan 50 to 100 100. The correlation between baseline plasma renin activity and reduction in peak and trough blood pressure at week 12, although statistically significant, was generally poor in the active treatment groups. In this trial, losartan was efficacious and well tolerated, and was similar to placebo with regard to adverse-experience profile. Adverse experiences that could reasonably be related to excessive lowering of blood pressure were not losartan 50 to 100 and there was no evidence of rebound hypertension.
2018 ©